Project Details
Description
The scope of product development activities that may be addressed through this award span manufacturing and formulation process development through clinical studies, including: manufacturing, characterization and release of pilot lot cGMP material; vaccine stability testing ; conduct of non-clinical studies, e.g., Investigational New Drug (IND)-enabling toxicology studies; development, qualification and, where necessary, validation of all assays and reagents needed to support product development; and the delivery to the NIAID of 2000 doses of cGMP bulk drug substance as well as 2000 doses of cGMP final container candidate.
| Status | Finished |
|---|---|
| Effective start/end date | 10/1/11 → 9/30/15 |
Funding
- National Institute of Allergy and Infectious Diseases: $4,874,885.00
- National Institute of Allergy and Infectious Diseases: $4,854,594.00
- National Institute of Allergy and Infectious Diseases: $2,237,069,911.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.